Aptamers and aptamer targeted delivery

RNA Biology

Volumn 6, Issue 3, 2009, Pages 316-320

  Yan, Amy C ^a   Levy, Matthew ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Aptamers; In vitro selection; SELEX; siRNA delivery; Targeted delivery

Indexed keywords

APTAMER;

CELL SURFACE; COMBINATORIAL CHEMISTRY; HUMAN; IN VITRO SELECTION; NONHUMAN; REVIEW; WHOLE CELL;

EID: 67650477343     PISSN: 15476286     EISSN: 15558584     Source Type: Journal    
DOI: 10.4161/rna.6.3.8808     Document Type: Review

References (59)

1. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: phase II study results. Ophthalmology 2003; 110:979-986 (Pubitemid 36560500)
2. Chan MY, Cohen MG, Dyke CK, Myles SK, Aberle LG, Lin M, et al. Phase 1b randomized study of antidote-controlled modulation of factor IXa activity in patients with stable coronary artery disease. Circulation 2008; 117:2865-2874 (Pubitemid 351787073)
3. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB Jr, Lorenz TJ, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. Jama 2005; 294:2446-2454 (Pubitemid 41627922)
4. Gilbert JC, DeFeo-Fraulini T, Hutabarat RM, Horvath CJ, Merlino PG, Marsh HN, et al. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007; 116:2678-2686 (Pubitemid 350291240)
5. Apte RS, Modi M, Masonson H, Patel M, Whitfield L, Adamis AP. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular agerelated macular degeneration. Ophthalmology 2007; 114:1702-1712
6. Ellington AD, Szostak JW. In vitro selection of RNA molecules that bind specific ligands. Nature 1990; 346:818-822
7. Sassanfar M, Szostak JW. An RNA motif that binds ATP. Nature 1993; 364:550-553 (Pubitemid 23273104)
8. Bock LC, Griffin LC, Latham JA, Vermaas EH, Toole JJ. Selection of single-stranded DNA molecules that bind and inhibit human thrombin. Nature 1992; 355:564-566
9. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase 1990; 249:505-510
10. Tuerk C, MacDougal S, Gold L. RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci USA 1992; 89:6988-6992
11. Lee JF, Hesselberth JR, Meyers LA, Ellington AD. Aptamer database. Nucleic Acids Res 2003; in press.
12. Yan AC, Bell KM, Breeden MM, Ellington AD. Aptamers: prospects in therapeutics and biomedicine. Front Biosci 2005; 10:1802-1827
13. Famulok M, Mayer G, Blind M. Nucleic acid aptamers-from selection in vitro to applications in vivo. Acc Chem Res 2000; 33:591-599
14. Famulok M, Hartig JS, Mayer G. Functional aptamers and aptazymes in biotechnology, diagnostics and therapy. Chem Rev 2007; 107:3715-3743 (Pubitemid 47534316)
15. Mairal T, Ozalp VC, Lozano Sanchez P, Mir M, Katakis I, O'Sullivan CK. Aptamers: molecular tools for analytical applications. Anal Bioanal Chem 2008; 390:989-1007. (Pubitemid 351207799)
16. Jayasena SD. Aptamers: an emerging class of molecules that rival antibodies in diagnostics. Clin Chem 1999; 45:1628-1650 (Pubitemid 29419030)
17. Keefe AD, Cload ST. SELEX with modified nucleotides. Curr Opin Chem Biol 2008; 12:448-456
18. Dollins CM, Nair S, Sullenger BA. Aptamers in immunotherapy. Hum Gene Ther 2008; 19:443-450
19. Li N, Wang Y, Pothukuchy A, Syrett A, Husain N, Gopalakrisha S, et al. Aptamers that recognize drug-resistant HIV-1 reverse transcriptase. Nucleic Acids Res 2008; 36:6739-6751
20. Misono TS, Kumar PK. Selection of RNA aptamers against human influenza virus hemagglutinin using surface plasmon resonance. Anal Biochem 2005. (Pubitemid 40884581)
21. Bianchini M, Radrizzani M, Brocardo MG, Reyes GB, Gonzalez Solveyra C, Santa-Coloma TA. Specific oligobodies against ERK-2 that recognize both the native and the denatured state of the protein. J Immunol Methods 2001; 252:191-197 (Pubitemid 32382103)
22. Cerchia L, Duconge F, Pestourie C, Boulay J, Aissouni Y, Gombert K, et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 2005; 3:123. (Pubitemid 40721162)
23. Pestourie C, Cerchia L, Gombert K, Aissouni Y, Boulay J, De Franciscis V, et al. Comparison of different strategies to select aptamers against a transmembrane protein target. Oligonucleotides 2006; 16:323-335 (Pubitemid 46043154)
24. Ulrich H, Magdesian MH, Alves MJ, Colli W. In vitro selection of RNA aptamers that bind to cell adhesion receptors of Trypanosoma cruzi and inhibit cell invasion. J Biol Chem 2002; 277:20756-20762
25. Blank M, Weinschenk T, Priemer M, Schluesener H. Systematic evolution of a DNA aptamer binding to rat brain tumor microvessels. selective targeting of endothelial regulatory protein pigpen. J Biol Chem 2001; 276:16464-16468 (Pubitemid 37391695)
26. Raddatz MS, Dolf A, Endl E, Knolle P, Famulok M, Mayer G. Enrichment of cell-targeting and population-specific aptamers by fluorescence-activated cell sorting. Angew Chem Int Ed Engl 2008; 47:5190-5193
27. Shangguan D, Li Y, Tang Z, Cao ZC, Chen HW, Mallikaratchy P, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci USA 2006; 103:11838-11843 (Pubitemid 44215773)
28. Shangguan D, Meng L, Cao ZC, Xiao Z, Fang X, Li Y, et al. Identification of liver cancerspecific aptamers using whole live cells. Anal Chem 2008; 80:721-728 (Pubitemid 351206860)
29. Chen HW, Medley CD, Sefah K, Shangguan D, Tang Z, Meng L, et al. Molecular Recognition of Small-Cell Lung Cancer Cells Using Aptamers. ChemMedChem 2008.
30. Berezovski MV, Lechmann M, Musheev MU, Mak TW, Krylov SN. Aptamer-facilitated biomarker discovery (AptaBiD). J Am Chem Soc 2008; 130:9137-9143
31. Xiao Z, Shangguan D, Cao Z, Fang X, Tan W. Cell-Specific Internalization Study of an Aptamer from Whole Cell Selection. Chemistry 2008; 14:1769-1775
32. Wang C, Zhang M, Yang G, Zhang D, Ding H, Wang H, et al. Single-stranded DNA aptamers that bind differentiated but not parental cells: subtractive systematic evolution of ligands by exponential enrichment. J Biotechnol 2003; 102:15-22. (Pubitemid 36369199)
33. Tang Z, Parekh P, Turner P, Moyer RW, Tan W. Generating Aptamers for Recognition of Virus-Infected Cells. Clin Chem 2009.
34. Borbas KE, Ferreira CS, Perkins A, Bruce JI, Missailidis S. Design and synthesis of monoand multimeric targeted radiopharmaceuticals based on novel cyclen ligands coupled to anti-MUC1 aptamers for the diagnostic imaging and targeted radiotherapy of cancer. Bioconjug Chem 2007; 18:1205-1212 (Pubitemid 47122643)
35. Hicke BJ, Stephens AW, Gould T, Chang YF, Lynott CK, Heil J, et al. Tumor targeting by an aptamer. J Nucl Med 2006; 47:668-678
36. Shangguan D, Cao ZC, Li Y, Tan W. Aptamers evolved from cultured cancer cells reveal molecular differences of cancer cells in patient samples. Clin Chem 2007; 53:1153-1155 (Pubitemid 46867534)
37. Li N, Ebright J, Stovall G, Chen X, Nguyen H, Singh A, et al. Technical and Biological Issues Relevant to Cell Typing by Aptamers. J Proteome Res 2009.
38. Hicke BJ, Stephens AW. Escort aptamers: a delivery service for diagnosis and therapy. J Clin Invest 2000; 106:923-928 (Pubitemid 30800848)
39. Bagalkot V, Zhang L, Levy-Nissenbaum E, Jon S, Kantoff PW, Langer R, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy and sensing of drug delivery based on bi-fluorescence resonance energy transfer. Nano Lett 2007; 7:3065-3070 (Pubitemid 350132931)
40. Gu F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, et al. Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 2008; 105:2586-2591
41. Zhang L, Radovic-Moreno AF, Alexis F, Gu FX, Basto PA, Bagalkot V, et al. Co-delivery of hydrophobic and hydrophilic drugs from nanoparticle-aptamer bioconjugates. ChemMedChem 2007; 2:1268-1271
42. McNamara JO, 2nd, Andrechek ER, Wang Y, Viles KD, Rempel RE, Gilboa E, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006; 24:1005-1015
43. Chu TC, Twu KY, Ellington AD, Levy M. Aptamer mediated siRNA delivery. Nucleic Acids Res 2006; 34:73.
44. Wullner U, Neef I, Eller A, Kleines M, Tur MK, Barth S. Cell-specific induction of apoptosis by rationally designed bivalent aptamer-siRNA transcripts silencing eukaryotic elongation factor 2. Curr Cancer Drug Targets 2008; 8:554-565
45. Song E, Zhu P, Lee SK, Chowdhury D, Kussman S, Dykxhoorn DM, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005; 23:709-717 (Pubitemid 41716361)
46. Dey AK, Khati M, Tang M, Wyatt R, Lea SM, James W. An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J Virol 2005; 79:13806-13810 (Pubitemid 41508193)
47. Zhou J, Li H, Li S, Zaia J, Rossi JJ. Novel Dual Inhibitory Function Aptamer-siRNA Delivery System for HIV-1 Therapy. Mol Ther 2008.
48. Chu TC, Marks JW, 3rd, Lavery LA, Faulkner S, Rosenblum MG, Ellington AD, et al. Aptamer:toxin conjugates that specifically target prostate tumor cells. Cancer Res 2006; 66:5989-5992
49. Chen CH, Dellamaggiore KR, Ouellette CP, Sedano CD, Lizadjohry M, Chernis GA, et al. Aptamer-based endocytosis of a lysosomal enzyme. Proc Natl Acad Sci USA 2008; 105:15908-15913
50. Huang YF, Shangguan D, Liu H, Phillips JA, Zhang X, Chen Y, et al. Molecular Assembly of an Aptamer-Drug Conjugate for Targeted Drug Delivery to Tumor Cells. Chembiochem 2009; 10:862-868
51. Arap W, Pasqualini R, Ruoslahti E. Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model. Science 1998; 279:377-380 (Pubitemid 28063372)
52. Trepel M, Pasqualini R, Arap W. Chapter 4 Screening Phage-Display Peptide Libraries for Vascular Targeted Peptides. Methods Enzymol 2008; 445:83-106.
53. Dollins CM, Nair S, Boczkowski D, Lee J, Layzer JM, Gilboa E, et al. Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. Chem Biol 2008; 15:675-682 (Pubitemid 351957907)
54. Cox JC, Hayhurst A, Hesselberth J, Bayer TS, Georgiou G, Ellington AD. Automated selection of aptamers against protein targets translated in vitro: from gene to aptamer. Nucleic Acids Res 2002; 30:108.
55. Mendonsa SD, Bowser MT. In vitro selection of high-affinity DNA ligands for human IgE using capillary electrophoresis. Anal Chem 2004; 76:5387-5392
56. Tok JB, Fischer NO. Single microbead SELEX for efficient ssDNA aptamer generation against botulinum neurotoxin. Chem Commun (Camb) 2008:1883-1885
57. Lou X, Qian J, Xiao Y, Viel L, Gerdon AE, Lagally ET, et al. Micromagnetic selection of aptamers in microfluidic channels. Proc Natl Acad Sci USA 2009; 106:2989-2994
58. Farokhzad OC, Cheng J, Teply BA, Sherifi I, Jon S, Kantoff PW, et al. Targeted nanoparticle- aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 2006; 103:6315-6320
59. Farokhzad OC, Jon S, Khademhosseini A, Tran TN, Lavan DA, Langer R. Nanoparticleaptamer bioconjugates: a new approach for targeting prostate cancer cells. Cancer Res 2004; 64:7668-7672 (Pubitemid 39446893)